Stocks and Investing Stocks and Investing
Fri, May 10, 2024

David Nierengarten Reiterated (ANAB) at Buy and Held Target at $34 on, May 10th, 2024


Published on 2024-10-28 11:14:00 - WOPRAI, David Nierengarten
  Print publication without navigation


David Nierengarten of Wedbush, Reiterated "AnaptysBio, Inc." (ANAB) at Buy and Held Target at $34 on, May 10th, 2024.

David has made no other calls on ANAB in the last 4 months.



There are 6 other peers that have a rating on ANAB. Out of the 6 peers that are also analyzing ANAB, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Anupam Rama of "JP Morgan" Maintained at Hold with Decreased Target to $28 on, Monday, April 1st, 2024


These are the ratings of the 5 analyists that currently disagree with David


  • David Risinger of "Leerink Partners" Initiated at Buy and Held Target at $47 on, Tuesday, April 16th, 2024
  • Derek Archila of "Wells Fargo" Initiated at Buy and Held Target at $56 on, Thursday, April 11th, 2024
  • Julian Harrison of "BTIG" Initiated at Strong Buy and Held Target at $55 on, Monday, February 26th, 2024
  • Alex Schwartz of "Stifel" Initiated at Strong Buy and Held Target at $50 on, Wednesday, February 21st, 2024
  • Yasmeen Rahimi of "Piper Sandler" Initiated at Buy and Held Target at $80 on, Friday, February 16th, 2024
Contributing Sources